Schranz Jennifer 4
4 · Nabriva Therapeutics plc · Filed Feb 10, 2020
Insider Transaction Report
Form 4
Schranz Jennifer
Chief Medical Officer
Transactions
- Award
Ordinary Shares
2020-02-06+105,000→ 158,705 total - Award
Stock Options
2020-02-06+210,000→ 210,000 totalExercise: $1.35Exp: 2030-02-05→ Ordinary Shares (210,000 underlying)
Footnotes (3)
- [F1]The reported transaction involved the reporting person's receipt of a grant of 105,000 restricted stock units. The total reported in Column 5 includes the 105,000 newly awarded restricted stock units.
- [F2]The option was granted on February 6, 2020, subject to shareholder approval; provided, that if such shareholder approval is not obtained, the option will remain outstanding and convert into a cash-settled share appreciation right.
- [F3]The option will vest over a four-year period beginning on February 6, 2020. Twenty-five percent (25%) of the option will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option will vest on a monthly pro-rata basis over the remaining vesting period.